ArticleBioactive materials2027
Benzothiazole derivatives target oligoadenylate synthetase and enhance RSV vaccine efficacy as adjuvants.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
2',5' oligoadenylate (2-5A) activates RNase L to degrade intracellular RNA and inhibit viral proliferation. The resulting nucleotide fragments bind RIG-I-like receptors to initiate type I interferon (IFN-I) signaling, enhancing maturation of antigen processing cells to trigger adaptive immunity. Moreover, 2-5A is an immune mediator to initiate neighboring cells for antiviral immunity. However, due to its short half-life in biological systems hinders its application in vaccine. Herein, we present a series of benzothiazole derivatives with modification at 2, 3, and 6 positions, that exhibit enhancing antigen immunogenicity. Among them, 3-benzyl-6-hydroxy-2-methylbenzo[d]thiazol-3-ium bromide and 3-benzyl-6-methoxy-2-methylbenzo[d]thiazol-3-ium bromide, named as CG and DG, significantly promoted dendritic cell maturation and elevated IgG titers when combination with model antigen OVA. By transcriptome sequencing analysis and knock out experiments, they activated 2-5A synthetase (OAS) to increase 2-5A production, and further was corroborated by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.